Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01156753 · ClinicalTrials.gov registry record · Phase 2
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase 2 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01156753 is a Phase 2 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 120 participants.
The verdict
NCT01156753, a Phase 2 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The main purpose of this study is to see whether CDX-011 is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not candidates for) all available approved therapies for their breast cancer. This study will also further characterize the safety of CDX-011 treatment in this patient population.
Interventions
- DRUG CDX-011
- DRUG "Investigator's Choice" chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01156753
The ClinicalTrials.gov registry entry for NCT01156753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CDX-011 is the first listed.
NCT01156753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01156753 about?
NCT01156753 is a clinical study titled "A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer". The main purpose of this study is to see whether CDX-011 is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not candidates for) all available approved therapies for their breast cancer. This s...
What is the current status of trial NCT01156753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2010-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01156753?
The interventions under investigation include: CDX-011 (DRUG), "Investigator's Choice" chemotherapy (DRUG).
Who is sponsoring clinical trial NCT01156753?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.